Long-term assessment of cyclophosphamide therapy for nephrosis in children.
D000293:Adolescent; D000367:Age Factors; D000505:Alopecia / Q000139:chemically induced; D001379:Azathioprine / Q000008:administration & dosage / Q000627:therapeutic use; D002648:Child; D002675:Child, Preschool; D003520:Cyclophosphamide / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D003556:Cystitis / Q000139:chemically induced; D004341:Drug Evaluation; D004347:Drug Interactions; D004359:Drug Therapy, Combination; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D007223:Infant; D007970:Leukopenia / Q000139:chemically induced; D008297:Male; D009404:Nephrotic Syndrome / Q000188:drug therapy*; D011241:Prednisone / Q000008:administration & dosage / Q000627:therapeutic use; D012008:Recurrence; D012075:Remission, Spontaneous; D012737:Sex Factors; D013997:Time Factors
D003520:Cyclophosphamide; D001379:Azathioprine; D011241:Prednisone